Elicio Therapeutics (ELTX) EBIT (2020 - 2026)

Elicio Therapeutics has reported EBIT for 7 years, with the latest figure at -$10.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 1.25% year-over-year to -$10.6 million; the trailing twelve-month figure through Mar 2026 stood at -$37.6 million (up 17.37% YoY), and the FY2025 full-year result was -$37.7 million, up 16.17% from the prior year.
• EBIT for Q1 2026 stood at -$10.6 million, down from -$8.8 million in the prior quarter.
• The five-year high for EBIT was -$5.8 million in Q3 2022, with the low at -$14.5 million in Q1 2022.
• Historically, EBIT has averaged -$9.5 million across 5 years, with a median of -$10.1 million in 2025.
• The largest YoY upside for EBIT was 65.84% in 2022 against a maximum downside of 140.73% in 2022.
• Elicio Therapeutics' EBIT stood at -$6.0 million in 2022, then sank by 57.56% to -$9.4 million in 2023, then sank by 43.48% to -$13.5 million in 2024, then surged by 34.39% to -$8.8 million in 2025, then decreased by 19.9% to -$10.6 million in 2026.
• The last three EBIT figures came in at -$10.6 million (Q1 2026), -$8.8 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.